We have finished the development of Brexiprazole. Please contact us for the details about the product and synthesis information.

 

 

CAS：913611-97-9

Molecular Formula：C₂₅H₂₇N₃O₂S

Molecular weight：433.6

Other names:  7-{4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy}quinolin-2(1H)-one, OPC-34712, D2 dopamine

Appearance：White to off-white powder

 

 

Brexpiprazole was first discovered by Otsuka Pharmaceutical Co Ltd. (Tokyo, Japan) and is being developed in collaboration with H. Lundbeck A/S (Valby, Denmark). It combines 5-HT1A receptor partial agonism and low-intrinsic activity D2 receptor partial agonism with antagonist activity on a variety of 5-HT and a-adrenergic receptors. The product is in Phase III development as an adjunctive therapy for MDD in the US and Europe, and is also being developed for the treatment of schizophrenia, anxiety disorders, dementia, post-traumatic stress disorder (PTSD), sleep disorders, and ADHD.

 

Major depressive disorder (MDD) is one of the most common psychiatric diseases around the world. The MDD market is a crowded and very competitive one, with more than 30 available d products for the treatment of patients with MDD. The depression market is about to enter a new phase with imminent patent expiries for top selling products, such as Eli Lilly's Cymbalta, and Otsuka/BMS's Abilify, along with the recent launch of the multimodal antidepressant, Lundbeck/Takeda's Brintellix, in January 2014, and the potential introduction of seven promising late-stage pipeline products into the market during the forecast period, from 2013 to 2023.